Pfizer reported positive early data from a bladder cancer trial combining its antibody-drug conjugate Padcev with Merck’s Keytruda. The combo extended event-free survival and overall survival in patients ineligible for chemotherapy in the perioperative setting. Padcev is currently approved for more advanced disease stages. Pfizer plans to discuss expanded indications with regulators. The drug is growing rapidly and expected to reach $2 billion sales by 2025, helping Pfizer offset declines in its COVID products.